Why the study?
Does levofloxacin 10-20 mg/kg once daily increase adverse events (musculoskeletal, serious adverse events, QT prolongation) in children treated for multidrug-resistant tuberculosis?
Does levofloxacin 10-20 mg/kg once daily increase adverse events (musculoskeletal, serious adverse events, QT prolongation) in children treated for multidrug-resistant tuberculosis?
Long-term levofloxacin use in children for multidrug-resistant tuberculosis appears safe and well tolerated, with no significant QT prolongation or serious adverse events.
Supports levofloxacin tolerability in pediatric MDR-TB; hypothesis-generating and requires randomized confirmation before practice change.
Safety concerns persist for long-term pediatric fluoroquinolone use. Seventy children (median age, 2.1 years) treated with levofloxacin 10-20 mg/kg once daily for multidrug-resistant tuberculosis (median observation time, 11.8 months) had few musculoskeletal events, no levofloxacin-attributed serious adverse events, and no Fridericia-corrected QT interval >450 ms. Long-term levofloxacin was safe and well tolerated.
No takes yet. Share an insight, caveat, or question.
Garcia‐Prats et al. (2018) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: